register

News & Trends - Pharmaceuticals

Medicine shortage alert – oral contraceptive pills

Health Industry Hub | August 26, 2020 |

Pharma News: Health professionals are advised that there is a shortage of Pfizer’s oral contraceptive pills Brevinor and Norimin (combination of ethinylestradiol and norethisterone).

Pfizer has advised the Therapeutic Goods Administration (TGA) the shortage of these products is due to manufacturing issues and is expected to continue until mid-October 2020 and early December 2020, depending on the product.

A spokesperson for Pfizer said “Due to a manufacturing delay there is a current shortage of some Pfizer oral contraceptives, including Norimin and Brevinor (Norethisterone+Ethinylestradiol). We are focused on providing a consistent supply of these contraceptives for patients, and are committed to actively resolving this matter.

Pfizer Australia is advising HCPs and pharmacists that normal supply for Pfizer’s oral contraceptives is expected in December 2020. Pfizer Australia advises patients who need to replenish their supply to discuss alternative contraception options with their doctor.”

The affected products are:

  • Brevinor – norethisterone 0.5 mg and ethinylestradiol 35 micrograms
  • Norimin – norethisterone 0.5 mg and ethinylestradiol 35 micrograms
  • Brevinor-1 – norethisterone 1 mg and ethinylestradiol 35 micrograms
  • Norimin-1 – norethisterone 1 mg and ethinylestradiol 35 micrograms.

There are currently no exact alternatives for these products. If patients have been prescribed Brevinor, Brevinor-1, Norimin or Norimin-1, HCPs may wish to consider an alternative combined oral contraceptive pill or methods of contraception.


News & Trends - Pharmaceuticals

Is the government is gearing up to release the long-awaited response to The New Frontier report?

Government’s long-awaited response to The New Frontier report unveiled after two-year wait

Health Industry Hub | December 1, 2023 |

Pharma News: The Albanese Government has tabled its response to the House of Reps inquiry and The New Frontier report […]

More


News & Trends - Pharmaceuticals

Gilead welcomes HIV Taskforce report and celebrates the 'unsung heroes'

Gilead welcomes HIV Taskforce report and celebrates the ‘unsung heroes’

Health Industry Hub | December 1, 2023 |

Pharma News: On World AIDS Day, the National Association of People with HIV Australia (NAPWHA) and Gilead Sciences Australia have […]

More


News & Trends - Pharmaceuticals

AbbVie secures PBS listing of first therapy for Crohn's disease in seven years

AbbVie secures PBS listing of first therapy for Crohn’s disease in seven years

Health Industry Hub | December 1, 2023 |

Pharma News: AbbVie’s Rinvoq (upadacitinib), a once-daily tablet, has been officially listed on the Pharmaceutical Benefits Scheme (PBS) for adult […]

More


ESG

New report calls on policy integration of sustainability in medical device and pharmaceutical registrations and funding

New report calls on policy integration of sustainability in medical device and pharmaceutical registrations and funding

Health Industry Hub | November 30, 2023 |

ESG: Increasing pressures from diverse stakeholder groups, spanning policymakers, investors, customers, and employees, have elevated Environmental, Social, and Governance (ESG) […]

More


This content is copyright protected. Please subscribe to gain access.